Vorasidenib
- Generic Name
- Vorasidenib
- Drug Type
- Small Molecule
- Chemical Formula
- C14H13ClF6N6
- CAS Number
- 1644545-52-7
- Unique Ingredient Identifier
- 789Q85GA8P
A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04015687
- Locations
- 🇺🇸
Celerion, Inc, Tempe, Arizona, United States
A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03960502
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 49
- Registration Number
- NCT03343197
- Locations
- 🇺🇸
United States, New York, New York, New York, United States
🇺🇸United States, California, San Francisco, California, United States
🇺🇸United States, Massachusetts, Boston, Massachusetts, United States
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia (AML)Hematologic MalignanciesMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02492737
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 95
- Registration Number
- NCT02481154
- Locations
- 🇺🇸
UCLA Oncology Center, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸University of Miami, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath